HIG Capital exits Celerion in $1.8bn sale

HIG Capital has sold clinical research organization Celerion Holdings to THL Partners for $1.8 billion, reflecting its Advantage strategy's success in generating significant returns. This sizable exit underscores the growing confidence in private equity markets, particularly in healthcare services. The deal highlights the ongoing trend of private equity firms realizing value from their investments as market conditions improve, which could set a precedent for future high-value transactions in the sector.